Linking pharmacometrics and health economic modelling to optimise the treatment of multi-drug resistant tuberculosis in the Asia-Pacific

  • Doan, Tan Nhut (Primary Chief Investigator (PCI))
  • Mcbryde, Emma S. (Chief Investigator (CI))
  • Trauer, James (Chief Investigator (CI))
  • Ragonnet, Romain (Chief Investigator (CI))

Project: Research

Project Details

Project Description

This project aims to link pharmacokinetics (PK, what the body does to the drug) and pharmacodynamics (PD, what the drug does to the body) to health economics to optimise the treatment of tuberculosis (TB) that is resistant to at least two anti-TB drugs, isoniazid and rifampicin (multi-drug resistant TB, MDR-TB). This project will focus on the Asia-Pacific region, where more than half of the global MDR-TB cases occur and the majority of imported MDR-TB cases in Australia come from. Combining PK-PD and health economics will provide strong evidence-base for designing optimal TB treatment strategy to improve patient outcomes.
Effective start/end date1/01/1731/12/17